NASDAQ:ENLV Enlivex Therapeutics Q4 2024 Earnings Report $1.10 -0.01 (-0.45%) As of 10:35 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Enlivex Therapeutics EPS ResultsActual EPS-$3.45Consensus EPS -$2.40Beat/MissMissed by -$1.05One Year Ago EPSN/AEnlivex Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEnlivex Therapeutics Announcement DetailsQuarterQ4 2024Date3/31/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEnlivex Therapeutics' Q1 2026 earnings is estimated for Friday, September 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, September 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(20-F) Enlivex Therapeutics Earnings HeadlinesEnlivex Therapeutics (ENLV) Projected to Release Quarterly Earnings on MondayAugust 30, 2026 | americanbankingnews.comEnlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Hold at Wall Street ZenAugust 29, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 9 at 1:00 AM | Chaikin Analytics (Ad)Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs JuneJuly 30, 2026 | globenewswire.comEnlivex Announces $400,000,000 Private PlacementJuly 28, 2026 | globenewswire.comEnlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 BillionJuly 20, 2026 | globenewswire.comSee More Enlivex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email. Email Address About Enlivex TherapeuticsEnlivex Therapeutics (NASDAQ:ENLV) is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings. The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system. Allocetra is currently being evaluated in clinical trials for indications such as sepsis, acute respiratory distress syndrome (ARDS), and cytokine storm associated with COVID-19. Enlivex’s pipeline also explores the potential of macrophage-based treatments to reduce complications in stem cell transplantation and support cancer therapies by mitigating treatment-related hyperinflammation. Enlivex collaborates with academic medical centers and contract research organizations across North America and Europe to advance its clinical programs. The management team brings expertise in immunology, cell therapy manufacturing, and regulatory affairs, positioning the company to scale production and pursue global regulatory approvals. Enlivex continues to build strategic partnerships aimed at broadening access to its cell-based immunotherapies for patients facing severe inflammatory disorders.View Enlivex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cathie Wood Trimmed Palantir, But the Bigger Story Is Still ValuationIntel’s ASML Milestone Gives Investors a New Reason to Revisit the StockDefense, Solar, and Refining Stocks Split as the Iran Conflict Raises Energy RiskLululemon’s Problems May Not Be a Warning for Every Athleticwear StockPayPal’s Takeover Story Ended, But Its Turnaround Story Didn’tDespite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom StockCampbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to Deliver Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
